Skip to content

A multicenter study of septin9 combined with fecal occult blood screening for colorectal cancer in Guangxi

A multicenter study of septin9 combined with fecal occult blood screening for colorectal cancer in Guangxi

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000038319
Enrollment
Unknown
Registered
2020-09-17
Start date
2019-09-01
Completion date
Unknown
Last updated
2020-12-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

Gold Standard:Colonoscopy and histopathology
Index test:Septin9&#32
with&#32

Sponsors

The First Affiliated Hospital of Guangxi Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 75 Years

Inclusion criteria

Inclusion criteria: Those who met any of the following 1-3 items were included in the study 1. Patients aged 50-75 years, both male and female; 2. Patients with positive fecal occult blood test (FOBT); 3. Patients with one of the following: previous history of colorectal adenomatous polyps / ulcerative colitis, Crohn's disease / first-degree relatives with history of colorectal cancer.

Exclusion criteria

Exclusion criteria: 1. Patients with a clear history of colorectal cancer; 2. Patients with rectal bleeding or hemorrhoids bleeding during screening; 3. Patients who underwent therapeutic biopsy during screening; 4. Patients diagnosed with cancer other than colorectal cancer; 5. Patients with known HIV, HBV and HCV infection.

Design outcomes

Primary

MeasureTime frame
Septin9;SEN, SPE, ACC, AUC of ROC;

Countries

China

Contacts

Public ContactJiang Haixing

Guangxi Medical University

jihaxi@163.com+86 13978867818

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 18, 2026